The US is planning to pursue a robust trade agenda in 2013.  There currently is a spirited debate regarding the inclusion of biologics in the free trade agreement (FTA) the US is negotiating with the Asia-Pacific region, the Trans- Pacific Partnership (TPP). Additionally, the US and the EU have recently announced a new trade agreement that will strengthen the economic ties between Europe and the United States. This panel will provide different perspectives on the benefits of trade as well as the opportunities and challenges presented by the inclusion of biologics in contemporary trade agreements. 

Learning Objectives:

  • Share the patient and scientist perspectives on biologics and trade
  • Highlight the potential impact of trade agreements on economies and health systems
  • Examine US trade policy going forward

Ability Level: All

Session ID: 1926

myBIO Chatter

Speakers (3)

User Thorsten Eickenhorst, MD, PhD, MBA Senior Vice President, US Chief Medical Officer and Head of US Development EMD Serono, Inc
User Brian Pomper Partner Akin Gump Strauss Hauer & Feld LLP
User Durhane Wong-Rieger, PhD Chair, International Alliance of Patients' Organizations Consumer Advocare Network

Moderators (1)

contact_9957 David Taylor Professor, Pharmaceutical and Public Health Policy The University College London School of Pharmacy